Published in:
Open Access 01-10-2019 | Insulins | Original Research
Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes
Published in: Diabetes Therapy | Issue 5/2019
Login to get accessAbstract
Introduction
EMOTION was a multinational, noninterventional study surveying current insulin-using adults with type 2 diabetes mellitus (T2D) who were initially reluctant to begin insulin treatment. In this Japanese population subanalysis of EMOTION, we identify the frequency and level of helpfulness of healthcare provider (HCP) actions, and we analyze life events (‘actions/events’) that assist T2D patients with psychological insulin resistance in the decision to initiate insulin.
Methods
Participants were selected from Survey Sampling International and their local partners’ market research panels in Japan. Quantitative surveys were administered between December 2016 and August 2017 to patients who met the study criteria. Participants were asked whether 45 actions/events occurred, and to rate the level of helpfulness of the actions/events in contributing to their decision to initiate insulin.
Results
Among the 594 eligible participating adults in the EMOTION study, 99 were from Japan. Despite initial reluctance to begin insulin treatment, 80.8% of the Japanese participants immediately commenced insulin. Practical demonstrations by HCPs on how to use insulin were rated by participants as most helpful. Examples of such practical demonstrations, reported as helping moderately or a lot, were ‘HCP walked patient through the process of exactly how to take insulin’ (82.8%), ‘HCP showed an insulin pen’ (79.7%), and ‘HCP helped patient to see how simple it was to inject insulin’ (79.1%).
Conclusion
This study identifies actions that HCPs can use to assist Japanese patients in deciding whether to initiate insulin. These findings may aid the development of clinical interventions addressing reluctance to begin insulin treatment among Japanese patients with T2D.
Funding
Eli Lilly and Company and Boehringer Ingelheim.
Plain Language Summary
Plain language summary available for this article.